Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus NEOSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus NEOSPORIN.
BACTROBAN vs NEOSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic